Metropolis Healthcare Ltd
Metropolis Healthcare Limited is one of the leading Indian diagnostics companies. The Company owns a chain of diagnostic centres across India, South Asia, Africa and the Middle East.
- Market Cap ₹ 11,452 Cr.
- Current Price ₹ 2,235
- High / Low ₹ 2,299 / 1,360
- Stock P/E 83.6
- Book Value ₹ 214
- Dividend Yield 0.18 %
- ROCE 15.8 %
- ROE 12.2 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company has been maintaining a healthy dividend payout of 21.3%
Cons
- Stock is trading at 10.4 times its book value
- The company has delivered a poor sales growth of 9.67% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
388 | 456 | 475 | 545 | 647 | 761 | 856 | 998 | 1,228 | 1,148 | 1,208 | 1,244 | |
285 | 339 | 359 | 405 | 467 | 559 | 619 | 708 | 880 | 855 | 920 | 946 | |
Operating Profit | 104 | 117 | 116 | 140 | 181 | 203 | 237 | 290 | 348 | 293 | 288 | 298 |
OPM % | 27% | 26% | 24% | 26% | 28% | 27% | 28% | 29% | 28% | 26% | 24% | 24% |
10 | 7 | 29 | 39 | 6 | 8 | -17 | 12 | 34 | 15 | 9 | 9 | |
Interest | 3 | 2 | 2 | 2 | 4 | 4 | 13 | 12 | 25 | 32 | 28 | 21 |
Depreciation | 16 | 21 | 17 | 17 | 19 | 20 | 39 | 46 | 63 | 89 | 94 | 99 |
Profit before tax | 95 | 101 | 128 | 160 | 164 | 187 | 169 | 244 | 293 | 188 | 175 | 187 |
Tax % | 34% | 33% | 36% | 33% | 32% | 34% | 24% | 25% | 27% | 24% | 26% | |
63 | 68 | 82 | 107 | 112 | 124 | 128 | 183 | 215 | 143 | 128 | 138 | |
EPS in Rs | 57.34 | 61.82 | 80.47 | 106.52 | 109.23 | 23.94 | 25.15 | 35.82 | 41.85 | 27.90 | 24.95 | 26.74 |
Dividend Payout % | 2% | 0% | 100% | 49% | 0% | 55% | 32% | 22% | 19% | 29% | 16% |
Compounded Sales Growth | |
---|---|
10 Years: | 12% |
5 Years: | 10% |
3 Years: | 7% |
TTM: | 9% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | 2% |
3 Years: | -11% |
TTM: | -1% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 12% |
3 Years: | -7% |
1 Year: | 52% |
Return on Equity | |
---|---|
10 Years: | 22% |
5 Years: | 21% |
3 Years: | 17% |
Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
Reserves | 292 | 352 | 269 | 314 | 405 | 408 | 513 | 696 | 876 | 978 | 1,086 |
20 | 14 | 5 | 1 | 1 | 18 | 67 | 112 | 379 | 266 | 197 | |
69 | 87 | 107 | 188 | 110 | 113 | 160 | 181 | 256 | 240 | 254 | |
Total Liabilities | 391 | 462 | 391 | 512 | 526 | 550 | 750 | 1,000 | 1,521 | 1,495 | 1,547 |
149 | 153 | 142 | 202 | 207 | 213 | 296 | 343 | 1,059 | 1,121 | 1,177 | |
CWIP | 1 | 0 | 1 | 1 | 0 | 6 | 3 | 0 | 6 | 20 | 0 |
Investments | 132 | 168 | 101 | 142 | 102 | 33 | 14 | 10 | 16 | 15 | 55 |
109 | 141 | 147 | 167 | 216 | 298 | 437 | 647 | 440 | 340 | 316 | |
Total Assets | 391 | 462 | 391 | 512 | 526 | 550 | 750 | 1,000 | 1,521 | 1,495 | 1,547 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|
77 | 69 | 91 | 102 | 104 | 90 | 215 | 249 | 253 | 247 | 264 | |
-61 | -56 | 96 | -86 | 1 | 36 | -104 | 63 | -736 | 48 | -89 | |
-14 | -9 | -174 | -17 | -87 | -118 | -55 | -33 | 163 | -292 | -181 | |
Net Cash Flow | 2 | 4 | 14 | -1 | 18 | 8 | 56 | 279 | -321 | 3 | -6 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 47 | 57 | 54 | 54 | 57 | 66 | 55 | 45 | 40 | 39 | 38 |
Inventory Days | 47 | 52 | 46 | 38 | 53 | 55 | 44 | 59 | 68 | 64 | 58 |
Days Payable | 75 | 92 | 96 | 97 | 88 | 90 | 152 | 160 | 136 | 136 | 150 |
Cash Conversion Cycle | 19 | 17 | 3 | -5 | 21 | 30 | -54 | -56 | -29 | -33 | -53 |
Working Capital Days | 22 | 32 | 8 | -27 | 28 | 42 | 11 | 4 | 14 | 14 | 7 |
ROCE % | 28% | 34% | 46% | 43% | 43% | 40% | 36% | 29% | 17% | 16% |
Documents
Announcements
-
Business Updates For Q2FY25
18h - Q2FY25 business update shows 13% revenue growth.
-
Closure of Trading Window
30 Sep - Closure of trading window until financial results are declared.
-
Announcement under Regulation 30 (LODR)-Credit Rating
27 Sep - CRISIL revises Metropolis Healthcare's credit ratings to AA-/Positive.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
16 Sep - Officials of the Company will be meeting Investors on September 23, 2024
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
13 Sep - Officials of the Company will be meeting Investors on September 19, 2024
Annual reports
Concalls
-
Aug 2024Transcript PPT
-
May 2024Transcript PPT REC
-
Feb 2024Transcript PPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Mar 2021Transcript PPT
-
Nov 2020TranscriptPPT
-
Nov 2020Transcript PPT
-
Aug 2020TranscriptPPT
-
Aug 2020Transcript PPT
-
May 2020Transcript PPT
-
Mar 2020TranscriptPPT
-
Feb 2020Transcript PPT
-
Nov 2019TranscriptNotesPPT
-
Sep 2019TranscriptPPT
-
Aug 2019Transcript PPT
-
Aug 2019TranscriptNotesPPT
-
Jul 2019TranscriptNotesPPT
-
Jul 2019TranscriptNotesPPT
-
May 2019Transcript PPT
Leading Diagnostics company[1] Metropolis Healthcare Ltd is the second largest Diagnostic company in India and the largest player in Western and Southern India.